Surface Oncology Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Surface Oncology Inc are shown below. This webpage includes a Q&A table on Surface Oncology Inc. This ESG score for Surface Oncology Inc indicates the company's transparency towards the United Nations SDGs.
Surface Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 8.0, social score of 3.2 and governance score of 4.0.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 687 | Valbiotis SA | 5.2 | High |
| 687 | Zeria Pharmaceutical Co Ltd | 5.2 | High |
| 724 | Surface Oncology Inc | 5.1 | High |
| 724 | Catalyst Pharmaceuticals Inc | 5.1 | High |
| 724 | Adverum Biotechnologies Inc | 5.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Surface Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Surface Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Surface Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Surface Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Surface Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Surface Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Surface Oncology Inc offer flexible work?
Sign up for free to unlockDoes Surface Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Surface Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Surface Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Surface Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Surface Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Surface Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Surface Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Surface Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Surface Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Surface Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Surface Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Surface Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Surface Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Surface Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Surface Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Surface Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Surface Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Surface Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Surface Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Surface Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Surface Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Surface Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Surface Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Surface Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Surface Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Surface Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Surface Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Surface Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Surface Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Surface Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.